Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of apatinib in recurrent or metastatic ovarian cancer
ChiCTR1800016539Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR1800016539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016539.